Coeptis Therapeutics Holdings Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
| ITEM 14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES |
|---|
The following table shows the fees paid or accrued for the audit and other services provided by Tuner, Stone & Company, LLP, our independent registered public accounting firm for the years ended December 31, 2023 and 2022.
| 12-31-2023 | 12-31-2022 | |||
| Audit fees | $73,912 | $49,886 | ||
|---|---|---|---|---|
| Other Service Fees | 145,440 | 61,995 | ||
| Total | $219,352 | $111,881 |
Audit fees consist of fees billed for services rendered for the audit of our consolidated financial statements included in this Annual Report on Form 10–K, and reviews of our quarterly condensed consolidated financial statements included in the Company’s quarterly filings on Form 10-Q.
Audit–related fees consist of fees reasonably related to the performance of the audit or review of the Company’s financial statements that are not reported as “Audit Fees.”
Tax fees consist of fees billed for professional services related to the preparation of our U.S. federal and state income tax returns and tax advice.
All other fees consist of fees for other miscellaneous items.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.